Abstract 1457: Genomic characterization of a PDX model of T-DM1-resistant HER2+ invasive ductal carcinoma using augmented exome sequencing
Authors: Elena Helman, Michael J. Wick, Michael J. Clark, Lizette Gamez, Sean Boyle, Kyriakos P. Papadopoulos, Shujun Luo, Anthony W. Tolcher, Parin Sripakdeevong, Mirian Karbelashvili, Deanna Church, Richard Chen, John West
Journal: Cancer Research (2015)

Abstract HER2 amplification/overexpression occurs in 20-30% of breast cancers and is associated with poor prognosis and increased metastatic potential. Patients with HER2+ breast cancers who have progressed on trastuzumab and lapatinib are often prescribed the antibody-drug conjugate, do-trastuzumab emtansine (T-DM1). Results from the TH3RESA and EMILIA studies showed that T-DM1 increased progression-free and overall survival compared to standard therapy and suggested it be considered as standard of care. Despite these favorable efficacy results, most patients treated with T-DM1 eventually progress, but the mechanisms of resistance are not understood. Acquired resistance to T-DM1 has been shown in-vitro, but has not been examined in an in-vivo system. An FNA from a metastatic lung lesion was used to establish a human PDX model from a patient with metastatic HER2+ invasive ductal carcinoma. This model was found resistant to T-DM1 administered weekly at 3 m/k and every three weeks at 10 m/k. We performed whole-exome sequencing on both the metastatic tissue and the PDX model using a content-enhanced exome technology we developed. Our augmented exome is optimized to detect major cancer mutations by enhancing coverage over known sequencing gaps and GC-rich regions across &amp;gt;1300 cancer and 200 miRNA genes. We also performed whole-transcriptome sequencing on the PDX model. All data were analyzed using a cancer bioinformatics pipeline optimized for high-accuracy detection of small variants and indels, somatic copy-number aberrations, gene expression and fusions. We comprehensively profiled the exomes of a metastatic HER2+ ductal carcinoma resistant to T-DM1 treatment and a PDX model derived from it. We found that the PDX model was highly consistent with the neoplastic tissue, with respect to both somatic variants and copy-number alterations, establishing it as an accurate representation of a patient-derived T-DM1-resistant tumor. We verified only 0.27% contamination by mouse DNA in the PDX model. Specifically, we confirmed the continued amplification of HER2 as well as CCNE1 and MYC. Loss-of-heterozygosity of TP53 was coupled with a clonal damaging point mutation. Of note, we found a non-synonymous mutation in HER2, suggesting possible involvement in resistance mechanisms. Transcriptome data confirmed mutation expression in the RNA and gene expression changes of amplified/deleted genes. We present the first preclinical model of a human xenograft derived from a HER2+ metastatic breast cancer with acquired T-DM1 resistance. T-DM1 is effective in treating advanced HER2+ breast cancer in patients who have progressed on standard therapies, but this efficacy is short-lived. Here, we used whole-exome and transcriptome sequencing to characterize the genomic profile of tumors that have become resistant to T-DM1 and present a patient-derived model to reveal insights into acquired T-DM1 resistance mechanisms. Citation Format: Elena Helman, Michael J. Wick, Michael J. Clark, Lizette Gamez, Sean Boyle, Kyriakos P. Papadopoulos, Shujun Luo, Anthony W. Tolcher, Parin Sripakdeevong, Mirian Karbelashvili, Deanna Church, Richard Chen, John West. Genomic characterization of a PDX model of T-DM1-resistant HER2+ invasive ductal carcinoma using augmented exome sequencing. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1457. doi:10.1158/1538-7445.AM2015-1457